Janux Therapeutics (JANX) Long-Term Debt Issuances (2020 - 2021)
Janux Therapeutics (JANX) posted quarterly Long-Term Debt Issuances of -$69.1 million for Q3 2021, down 1646.97% year-over-year from $4.5 million in Q3 2020, and down 200.4% quarter-over-quarter from $68.8 million in Q2 2021.
Powered by 
Analysis
Janux Therapeutics (JANX) Long-Term Debt Issuances (2020 - 2021) Analysis & Trends
Janux Therapeutics (JANX) has reported Long-Term Debt Issuances for 2 consecutive years, with -$69.1 million the latest figure, recorded in Q3 2021.
- In Q3 2021, Long-Term Debt Issuances fell 1646.97% year-over-year to -$69.1 million; the TTM figure through Jun 2022 stood at -$69.1 million (down 155.36% YoY), while the FY2021 annual figure was $55.7 million, changed N/A from the prior year.
- Long-Term Debt Issuances fell to -$69.1 million in Q3 2021 per JANX's latest filing, from $68.8 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $68.8 million in Q2 2021 and bottomed at -$69.1 million in Q3 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Janux Therapeutics | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2021 | 68.83 Mn |
| Mar 31, 2021 | 56.00 Mn |
| Dec 31, 2020 | 4.49 Mn |
| Sep 30, 2020 | -33,000.00 |